Regulatory

Brazil ANVISA Botanical Medicine Framework: How EBC-46 Supplements Are Classified

A neutral overview of how Brazil's ANVISA classifies botanical products and how EBC-46 / blushwood berry supplements would fit within the country's tiered regulatory pathways.

Consumer Reports

EBC-46 Supplement Timing With Other Botanicals: User Reports on Stack Compatibility

Aggregated user reports on how readers schedule blushwood berry extract alongside other botanicals — timing patterns, perceived tolerability, and practical notes.

Natural Source

Shade Tolerance and Light Requirements in Fontainea picrosperma: Cultivating the Blushwood Berry

Fontainea picrosperma is a rainforest understorey species with specific photosynthetic light demands. Implications for cultivation and consistent EBC-46 yield.

Human Trials

CTCAE Adverse Event Grading in Tigilanol Tiglate Trials: How EBC-46 Clinical Safety Is Measured

CTCAE v5.0 framework explained — how Common Terminology Criteria for Adverse Events grade severity in tigilanol tiglate (EBC-46) clinical trials.

Mechanism of Action

Immunogenic Cell Death and DAMPs: How EBC-46 (Tigilanol Tiglate) Recruits the Immune System Against Tumours

How EBC-46 / tigilanol tiglate triggers immunogenic cell death and releases damage-associated molecular patterns to recruit innate and adaptive anti-tumour immunity.

Regulatory

Health Canada NHPD: How EBC-46 Botanical Supplements Are Classified Under Canadian Natural Health Product Regulations

Examining how Canadian Natural Health Product regulations under Health Canada's NHPD classify blushwood berry extract supplements containing EBC-46.

Consumer Reports

Taking EBC-46 Supplements With Meals: User Reports on Food Effect and Tolerability

How users describe taking blushwood berry extract supplements with food versus on an empty stomach, anecdotal patterns around stomach comfort, perceived absorption, and routine fit.

Natural Source

Tissue Culture Micropropagation of Fontainea picrosperma: Scaling Blushwood Cultivation

How in vitro micropropagation techniques are being explored for Fontainea picrosperma, the slow-growing rainforest tree behind blushwood berry extract, and the technical hurdles involved.

Human Trials

Pharmacokinetic Profile of Tigilanol Tiglate: Cmax, AUC, and Half-Life in Phase I Studies

A look at published systemic exposure data for intratumoral tigilanol tiglate, what plasma concentration measurements have shown about local versus systemic drug distribution.

Mechanism of Action

Caspase-Mediated Apoptosis in EBC-46 Tumour Cell Death: The Executioner Pathway

How caspase-3 and caspase-9 activation contributes to programmed tumour cell death following tigilanol tiglate exposure, and what cell-line studies have observed downstream.

Regulatory

Mexico COFEPRIS and EBC-46 Botanical Supplements: Classification and Import Pathway

How Mexico's COFEPRIS classifies imported botanical supplements like blushwood berry extract under the suplemento alimenticio framework, and what documentation matters at customs.

consumer

Capsule Swallowing Experience for EBC-46 Supplements: A User-Reports Overview

What consumers report about swallowing EBC-46 capsules — size, coating, water needs, and how routines compare with the tincture format.